Purpose/Objectives: To examine daily fatigue patterns during the third cycle of chemotherapy in women with breast cancer and predict whether fatigue trajectories differ by exercise or chemotherapy regimens.
Design: A secondary data analysis.
Setting: Five cancer centers in the San Francisco Bay area.
Sample: 98 female outpatients with breast cancer receiving chemotherapy.
Methods: The data were collected as part of a randomized clinical trial to test the effectiveness of a systematic exercise intervention on fatigue. Participants were classified as exercisers or nonexercisers according to the Surgeon General's Guideline for Physical Activity criteria. Average and worst fatigue levels in the prior 24 hours were measured on a 0-10 numeric rating scale at bedtime for 21 consecutive days beginning on the day of chemotherapy.
Main Research Variables: Average and worst levels of fatigue, exercise status, and chemotherapy regimens.
Findings: Average and worst levels of fatigue peaked immediately after chemotherapy and declined gradually over time. The decreases were significant (p < 0.001) but not different between exercisers and nonexercisers. Fatigue of doxorubicin and cyclophosphamide (AC) regimens was more severe, especially for the first three days after chemotherapy, and more prolonged than those of non-AC regimens.
Conclusions: The patterns of change in fatigue were similar between exercisers and nonexercisers, but nonexercisers consistantly reported higher fatigue levels during the third cycle of chemotherapy. The patterns of fatigue differed by chemotherapy regimens.
Implications for Nursing: The information of fatigue trajectories is crucial in preparing patients for chemotherapy and determining the timing of interventions and measurement of outcomes.